Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991938 | 1.00 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL34 | 1.00 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL5068661 | 1.00 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| P-Xylene SCHEMBL8660591 | 1.00 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL11432043 | 1.00 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1705904 | 1.00 | GAA (0.62) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1594407 | 0.97 | GAA (0.59) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| Water SCHEMBL214962 | 0.97 | GAA (0.59) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1345322 | 0.97 | GAA (0.59) | GAALMNAALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL22802539 | 0.97 | GAA (0.59) | GAALMNAALDH1A1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2025111563-A1 | MILK PEPTIDE COMPOSITIONS FOR PHARMACEUTICAL AND COSMECEUTICAL USE | MATRUBIALS INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| CN-115197116-A | Preparation method of N-phenylmaleimide | 中国石油化工股份有限公司 | 2022-10-18 | — | — | CN | claimed |
| US-20120046471-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | SALTIGO GMBH (DE) | 2012-02-23 | — | — | US | claimed |
| US-20120029044-A1 | 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | THERON PHARMACEUTICALS INC. | 2012-02-02 | — | — | US | claimed |
| US-8030520-B2 | Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide | SALTIGO GMBH (DE) | 2011-10-04 | — | — | US | claimed |
| EP-2107047-B1 | Method for producing organic compounds by means of a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halogenide | SALTIGO GMBH (DE) | 2011-09-28 | — | — | EP | claimed |
| US-20110220844-A1 | SULFONATE MODIFIED NANOCRYSTALS | Life Technologies Corporation | 2011-09-15 | — | — | US | claimed |
| JP-2011524897-A | — | — | 2011-09-08 | — | — | JP | claimed |
| US-8003617-B2 | e.g. 1-(3',4'-ethylenedioxy)phenyl-2-nonanoylamino-3-pyrrolidino-1-propanol; glucosylceramide synthase inhibitor; inhibits glycosphingolipid synthesis; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, Gaucher's disease | GENZYME CORPORATION (US) | 2011-08-23 | — | — | US | claimed |
| WO-2011094434-A2 | 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | THERON PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | claimed |
| EP-2342161-A2 | SULFONATE MODIFIED NANOCRYSTALS | Life Technologies Corporation (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | claimed |
| EP-2303266-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| US-20110053987-A1 | PYRIDINIUM AND THIAZOLIUM CONJUGATES INCLUDING POLYETHYLENE GLYCOLS AND METHODS OF USING THE SAME | MYCOSOL, INC. | 2011-03-03 | — | — | US | claimed |
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | claimed |
| EP-4705244-A1 | AN EFFICIENT SEPARATION PROCESS FOR RARE EARTH ELEMENT COMPOUNDS AND NOVEL RARE EARTH ELEMENT COMPLEXES USED THEREFOR | ETH Zürich (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-0213925-A2 | Copolymerizable UV stabilizers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-03-11 | — | — | EP | disclosed |
| US-4198424-A | ANALGESICS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053987-A1 | PYRIDINIUM AND THIAZOLIUM CONJUGATES INCLUDING POLYETHYLENE GLYCOLS AND METHODS OF USING THE SAME | PLPBP, PTPMT1, PNPO | GAA 1009/4885LMNA 4609/4885ALDH1A1 3076/4885 |
| US-20120046471-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | TIMCC, ZFX, TSNAX | GAA 1520/4885LMNA 2952/4885ALDH1A1 3382/4885 |
| US-20120029044-A1 | 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | CHRM3, CHRM2, CHRM1 | GAA 3001/4885LMNA 3992/4885ALDH1A1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.